From: The role of a multidisciplinary team in the management of portal hypertension
 | Global Population (n = 528) | Propensity Score Matching (n = 169) | ||||
---|---|---|---|---|---|---|
MDT (n = 86) | Non-MDT (n = 442) | P-value | MDT (n = 58) | Non-MDT (n = 111) | P-value | |
General Characteristics | ||||||
Gender | ||||||
 Male | 59 (68.6%) | 292 (66.1%) | 0.74 | 39 (67.2%) | 88 (79.3%) | 0.275 |
 Female | 27 (31.4%) | 150 (33.9%) |  | 19 (32.8%) | 23 (20.7%) | |
Age (years) | 52.91 ± 13.08 | 53.63 ± 10.55 | 0.579 | 51.76 ± 12.39 | 50.68 ± 11.73 | 0.089 |
Child Pugh Classification | ||||||
 Class A | 44 (51.2%) | 224 (50.7%) | 0.371 | 28 (48.3%) | 55 (49.5%) | 0.761 |
 Class B | 41 (47.7%) | 199 (45%) |  | 29 (50.0%) | 52 (46.8%) | |
 Class C | 1 (1.2%) | 19 (4.3%) |  | 1 (1.7%) | 4 (3.6%) | |
MELD Score | 7.04 ± 4.59 | 6.57 ± 4.23 | 0.359 | 7.51 ± 4.09 | 7.22 ± 3.78 | 0.64 |
Etiology of Portal Hypertension | ||||||
 Viral Hepatitis | 46 (53.5%) | 254 (57.5%) | 0.027 | 35 (60.3%) | 60 (54.1%) | 0.894 |
 Alcohol | 4 (4.7%) | 40 (9%) |  | 2 (3.4%) | 8 (7.2%) | |
 AIH/PBC | 5 (5.8%) | 54 (12.2%) |  | 4 (6.9%) | 7 (6.3%) | |
 Schistosomiasis | 9 (10.5%) | 19 (4.3%) |  | 6 (10.3%) | 10 (9.0%) | |
 Others | 19 (22.1%) | 66 (14.9) |  | 10 (17.2%) | 23 (20.7%) | |
 Mixed | 3 (3.5%) | 9 (2%) |  | 1 (1.7%) | 3 (2.7%) | |
Received Previous Treatment | 37 (43.0%) | 95 (21.5%) | < 0.001 | 30 (51.7%) | 53 (47.7%) | 0.742 |
Concurrent Conditions | ||||||
Portal Venous Thrombosis | 0.841 | |||||
 Absent | 53 (61.6%) | 351 (79.4%) | 0.005 | 52 (89.7%) | 102 (91.9%) | |
 Present | 33 (38.4%) | 91 (20.6%) |  | 6 (10.3%) | 9 (8.1%) | |
Hepatic Cellular Carcinoma | 0.886 | |||||
 Absent | 77 (89.5%) | 413 (93.4%) | 0.292 | 50 (86.2%) | 98 (88.3%) | |
 Present | 9 (10.5%) | 29 (6.6%) |  | 8 (13.8%) | 13 (11.7%) | |
Endoscopic Examination | ||||||
Gastroesophageal Classification | ||||||
 EV | 16 (18.6%) | 133 (30.1%) | < 0.001 | 14 (24.1%) | 35 (31.5%) | 0.158 |
 GOV Type 1 | 23 (26.7%) | 275 (62.2%) | 19 (32.8%) | 46 (41.4%) | ||
 GOV Type 2 | 30 (34.9%) | 18 (4.1%) | 16 (27.6%) | 16 (14.4%) | ||
 IGV Type 1 | 17 (19.8%) | 16 (3.6%) | 9 (15.5%) | 14 (12.6%) | ||
Treatment Received | ||||||
 Pharmacological Treatment | 12 (14%) | 8 (1.8%) | < 0.001 | 8 (13.8%) | 8 (7.2%) | 0.004 |
 Endoscopy | 28 (32.6%) | 375 (84.8%) | 26 (44.8%) | 68 (61.3%) | ||
 Surgery | 7 (8.1%) | 48 (10.9%) | 7 (12.1%) | 24 (21.6%) | ||
 Interventional Radiology | 37 (43%) | 8 (1.8%) | 15 (25.9%) | 8 (7.2%) | ||
 Combined Therapy | 2 (2.3%) | 3 (0.7%) | 2 (3.4%) | 3 (2.7%) |